Decoding the means to cancer’s
end.
At Freenome, we’re developing next-generation blood tests for early cancer detection, powered by our multiomics platform.
Moving early cancer detection forward, for all
There is no blueprint for putting an end to cancer. That’s why Freenomers push to achieve what is now possible to discover the body’s earliest warning signs of cancer, and develop accessible tests to detect cancer in its earliest, most treatable stages.
LEARN ABOUT OUR APPROACH
Using a standard blood draw for early cancer detection
We are developing early cancer detection blood tests tailored to different types of cancer by looking at biomarkers from both tumor and non-tumor-derived sources to detect the body’s earliest warning signs of cancer.
LEARN ABOUT OUR BLOOD TESTSDecoding hidden patterns
Our blood tests are being developed using our multiomics platform, which combines our deep expertise in molecular biology and machine learning to identify cancer-associated patterns among billions of circulating biomarkers from tumor and non-tumor-derived sources. We also partner with health systems to integrate actionable insights and create a feedback loop between care and science.
LEARN ABOUT OUR MULTIOMICS PLATFORM